Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 14752 participants.

Also called NCT01144338

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 14,752 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01144338
Other papers using this trial's data
  • Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) Diabetes care, 2019-06 DOI, PubMed 31010875, PMC6973544 Not in the PMC Open Access subset.
  • Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial Circulation. Cardiovascular interventions, 2019-12 DOI, PubMed 31752517
  • Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL Diabetes care, 2020-03 DOI, PubMed 31882409
  • Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) Cardiovascular diabetology, 2022-06-27 DOI, PubMed 35761271, PMC9238154 In the PMC Open Access subset under CC BY.
  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes The New England journal of medicine, 2017-09-28 DOI, PubMed 28910237, PMC9792409 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial Diabetes, obesity & metabolism, 2024-10 DOI, PubMed 39086032
  • Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes Circulation, 2020-04-28 DOI, PubMed 32098501
  • Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial Alzheimer's research & therapy, 2024-10-02 DOI, PubMed 39358806, PMC11448378 In the PMC Open Access subset under CC BY.
  • Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) Diabetes care, 2020-02 DOI, PubMed 31806653, PMC7210004 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01144338. Randomized; triple masking; primary purpose treatment. Start 2010-06-18 (actual); primary completion 2017-04-21 (actual). Results posted on 2018-08-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Exenatide Once Weekly
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01144338
Content hash
96c4adb46b4713fd1675ebea8b22f88c6cfa918dc3065465aab86fcc163540d1